NASDAQ: PRPH - ProPhase Labs, Inc.

Yield per half year: -80.99%
Dividend yield: 0.00%
Sector: Healthcare

Share chart ProPhase Labs, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About ProPhase Labs, Inc.

ProPhase Labs, Inc. engages in the development and commercialization of novel drugs, dietary supplements, and compounds in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It provides a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.

more details
The company also offers contract manufacturing services, such as consumer product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, it is involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 1997-01-16
ISIN US74345W1080
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0
Дивиденд ао 0.3
Сайт https://www.prophaselabs.com
Цена ао 0.48
Change price per day: 0% (0.46)
Change price per week: +48.96% (0.3088)
Change price per month: +4.52% (0.4401)
Change price per 3 month: -27.79% (0.637)
Change price per half year: -80.99% (2.42)
Change price per year: -92.89% (6.47)
Change price per 3 year: -93.79% (7.41)
Change price per 5 year: -75.14% (1.85)
Change price per year to date: -27.4% (0.6336)
All parameters

Underestimation

Title Value Grade
P/S 1.8 8
P/BV 1.62 8
P/E 9.69 9
EV/EBITDA -6.64 0
Total: 7.75

Efficiency

Title Value Grade
ROA, % -18.26 0
ROE, % -33.98 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0.7 7
Total: 3.43

Debt

Title Value Grade
Debt/EBITDA -0.875 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 348.32 10
Yield Ebitda, % 429.54 10
Yield EPS, % 274.4 10
Total: 10
More

Institutions Volume Share, %
Vanguard Group Inc 609347 3.38
Renaissance Technologies, LLC 245710 1.36
HighTower Advisors, LLC 173124 0.96
Geode Capital Management, LLC 137409 0.76
Perritt Capital Management, Inc. 85900 0.48
Blackrock Inc. 60754 0.34
SVB Wealth LLC 47665 0.26
Northern Trust Corporation 45962 0.25
Bank Of New York Mellon Corporation 42531 0.24
State Street Corporation 40163 0.22

ETFShare, %Profitability for 1 year, %Dividends, %
iShares Micro-Cap ETF 0.00983 17.09 1.54048
0.0117.091.54



Head Job title Payment Year of birth
Mr. Ted William Karkus Chairman & CEO 902.2k 1959 (66 years)
Mr. Sergio Miralles Executive VP & Chief Information Officer N/A
Mr. Kamal Obbad Senior VP and Director of Sales & Marketing - Nebula Genomics N/A
Mr. Jason Karkus President of Nebula Genomics N/A
Mr. Jed A. Latkin Chief Operating Officer & Head of Finance Department N/A 1974 (51 year)
Mr. Lance Bisesar Corporate Controller

Address: United States, Garden City. NY, 711 Stewart Avenue - open in Google maps, open in Yandex maps
Website: https://www.prophaselabs.com